GlassScriptPhysician profile
Amy L Mclean
NPI 1356796874
$3,701.16
in general payments reported to CMS, 2019-2025
29 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $564 · 2023: $741 · 2024: $576 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Education: $20.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.67 |
| Education | $20.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.42 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $605.45 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $435.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $262.39 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $208.61 | 2021-2024 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $192.84 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $167.30 | 2022-2025 | Qelbree |
| Alkermes, INC. | $158.41 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $148.14 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $125.96 | 2021-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $101.81 | 2022-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $74.81 | 2025 | Jornay Pm |
| Novo Nordisk INC | $67.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $37.19 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $24.60 | 2022-2023 | Freestyle Libre 2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.20 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $23.31 | 2024 | Capvaxive, Vaxneuvance |
| Lundbeck LLC | $22.84 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $22.81 | 2021 | |
| Dexcom, INC. | $20.66 | 2021 | |
| Eisai INC. | $20.44 | 2021 | |
| Cranial Technologies, INC | $19.17 | 2024 | Doc Band |
| Medtronic, INC. | $18.41 | 2025 | Inceptiv |
| Lilly USA, LLC | $16.85 | 2023 | Mounjaro, Trulicity |
| Sunovion Pharmaceuticals INC. | $15.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2023 | Xifaxan |
| Jazz Pharmaceuticals INC. | $13.59 | 2021 | |
| Pfizer INC. | $12.82 | 2022 | |
| Almatica Pharma LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.